Last reviewed · How we verify

Lamivudine+Oxymatrine Capsules

Southeast University, China · FDA-approved active Small molecule

Lamivudine+Oxymatrine Capsules is a Nucleoside reverse transcriptase inhibitor + herbal immunomodulator Small molecule drug developed by Southeast University, China. It is currently FDA-approved for Chronic hepatitis B infection, HIV infection (as part of combination antiretroviral therapy).

Lamivudine inhibits reverse transcriptase to suppress viral replication, while oxymatrine provides immunomodulatory and hepatoprotective effects.

Lamivudine inhibits reverse transcriptase to suppress viral replication, while oxymatrine provides immunomodulatory and hepatoprotective effects. Used for Chronic hepatitis B infection, HIV infection (as part of combination antiretroviral therapy).

At a glance

Generic nameLamivudine+Oxymatrine Capsules
SponsorSoutheast University, China
Drug classNucleoside reverse transcriptase inhibitor + herbal immunomodulator
TargetReverse transcriptase; oxymatrine targets multiple immune pathways (non-specific)
ModalitySmall molecule
Therapeutic areaVirology / Hepatology
PhaseFDA-approved

Mechanism of action

Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV and hepatitis B virus replication by inhibiting reverse transcriptase. Oxymatrine, an alkaloid from Sophora flavescens, has immunomodulatory properties and may enhance antiviral immunity while providing hepatoprotective effects. The combination targets both viral suppression and immune enhancement in chronic viral infections.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Lamivudine+Oxymatrine Capsules

What is Lamivudine+Oxymatrine Capsules?

Lamivudine+Oxymatrine Capsules is a Nucleoside reverse transcriptase inhibitor + herbal immunomodulator drug developed by Southeast University, China, indicated for Chronic hepatitis B infection, HIV infection (as part of combination antiretroviral therapy).

How does Lamivudine+Oxymatrine Capsules work?

Lamivudine inhibits reverse transcriptase to suppress viral replication, while oxymatrine provides immunomodulatory and hepatoprotective effects.

What is Lamivudine+Oxymatrine Capsules used for?

Lamivudine+Oxymatrine Capsules is indicated for Chronic hepatitis B infection, HIV infection (as part of combination antiretroviral therapy).

Who makes Lamivudine+Oxymatrine Capsules?

Lamivudine+Oxymatrine Capsules is developed and marketed by Southeast University, China (see full Southeast University, China pipeline at /company/southeast-university-china).

What drug class is Lamivudine+Oxymatrine Capsules in?

Lamivudine+Oxymatrine Capsules belongs to the Nucleoside reverse transcriptase inhibitor + herbal immunomodulator class. See all Nucleoside reverse transcriptase inhibitor + herbal immunomodulator drugs at /class/nucleoside-reverse-transcriptase-inhibitor-herbal-immunomodulator.

What development phase is Lamivudine+Oxymatrine Capsules in?

Lamivudine+Oxymatrine Capsules is FDA-approved (marketed).

What are the side effects of Lamivudine+Oxymatrine Capsules?

Common side effects of Lamivudine+Oxymatrine Capsules include Lactic acidosis, Hepatotoxicity, Pancreatitis, Peripheral neuropathy, Gastrointestinal disturbance.

What does Lamivudine+Oxymatrine Capsules target?

Lamivudine+Oxymatrine Capsules targets Reverse transcriptase; oxymatrine targets multiple immune pathways (non-specific) and is a Nucleoside reverse transcriptase inhibitor + herbal immunomodulator.

Related